GlassScriptPhysician profile
Michael J Krier
NPI 1497808414
$6,719.98
in general payments reported to CMS, 2019-2025
41 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $267 · 2021: $550 · 2022: $735 · 2023: $959 · 2024: $1,508 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,072.95 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $618.55 | 2019-2025 | Stelara, Tremfya, Simponi |
| Lilly USA, LLC | $413.82 | 2023-2025 | Omvoh, Amyvid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.60 | 2019-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $260.43 | 2019-2025 | |
| Qol Medical, LLC | $218.62 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $199.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $167.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.42 | 2023-2024 | Zeposia |
| Organon LLC | $118.24 | 2024-2025 | Hadlima |
| Celgene Corporation | $107.52 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $107.28 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $99.52 | 2019 | |
| Tanabe Pharma America, INC. | $68.74 | 2023-2025 | Radicava |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $67.11 | 2020-2025 | Sutab, Suflave |
| Shionogi INC | $62.27 | 2019 | |
| Merck Sharp & Dohme LLC | $53.13 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $52.51 | 2023-2024 | Ultomiris |
| Amneal Pharmaceuticals LLC | $51.72 | 2022-2025 | Crexont |
| Celltrion USA INC. | $51.59 | 2024-2025 | Vegzelma |
| Banner Life Sciences, LLC | $48.13 | 2024 | |
| Argenx US, INC. | $43.46 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Olympus America INC. | $42.15 | 2022-2023 | Visiglide |
| Allergan, INC. | $39.22 | 2019 | |
| Neurocrine Biosciences, INC. | $35.04 | 2022 | |
| Aimmune Therapeutics, INC. | $33.95 | 2024-2025 | Vowst |
| Sandoz INC. | $33.70 | 2024 | Hyrimoz |
| Ardelyx, INC. | $28.22 | 2025 | Ibsrela |
| Genzyme Corporation | $28.07 | 2023 | |
| Merz Pharmaceuticals, LLC | $26.80 | 2025 | Xeomin |
| Daiichi Sankyo INC. | $24.85 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.59 | 2025 | Iqirvo |
| Janssen Pharmaceuticals, INC | $23.10 | 2022 | |
| Redhill Biopharma INC. | $22.71 | 2021 | |
| Dova Pharmaceuticals | $19.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.29 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.19 | 2025 | Voquezna |
| Viiv Healthcare Company | $16.42 | 2024 | Apretude |
| Biogen, INC. | $15.59 | 2024 | Tysabri, Vumerity |
| Lundbeck LLC | $14.84 | 2023 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.